Clinical Trials

86 results for Prostate Cancer


A Phase III Randomized Study of Hypofractionated Image-guided Volumetric Modulated Arc Radiotherapy (IG-VMAT) Versus Conventionally Fractionated IG-VMAT in Patients With Localized Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Radiation: hypofraction, Radiation: convention
  • Study ID: NCT02934685
View Trial

A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Biological: ProstAtak®(AdV-tk) + valacyclovir, Biological: Placebo + valacyclovir
  • Study ID: NCT01436968
View Trial

A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

  • Condition: Adenocarcinoma of Prostate, Progression of Prostate Cancer
  • Intervention: Drug: Cabazitaxel, Radiation: Pelvic radiotherapy, Radiation: prostate radiotherapy
  • Study ID: NCT01952223
View Trial

Prospective Evaluation of CyberKnife® as Monotherapy or Boost Stereotactic Body Radiotherapy for Intermediate or High Risk Localized Prostate Cancer

  • Condition: Prostate Adenocarcinoma
  • Intervention: Radiation: CyberKnife, Other: Androgen Deprivation Therapy (ADT), Radiation: Intensity Modulated radiation therapy (IMRT)
  • Study ID: NCT01985828
View Trial

Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy

  • Condition: Prostate Cancer
  • Study ID: NCT01961713
View Trial

Evaluation of the TULSA-PRO MRI-guided Transurethral Ultrasound Prostate Ablation Device in Patients With Localized Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Device: MRI-guided Transurethral Ultrasound Ablation
  • Study ID: NCT02766543
View Trial

A Pilot Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) to Detect High Grade Localized Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Pyruvate (13C)
  • Study ID: NCT02526368
View Trial

The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.

  • Condition: Prostate Cancer
  • Intervention: Other: Active surveillance
  • Study ID: NCT00949819
View Trial

Prospective Evaluation of CyberKnife Stereotactic Body Radiotherapy for Localized Prostate Cancer: Risk Stratified Monotherapy Versus Boost

  • Condition: Prostate Cancer
  • Intervention: Radiation: Stereotactic Ablative Body Radiotherapy as Monotherapy, Radiation: Stereotactic Ablative Body Radiotherapy as a Boost
  • Study ID: NCT02016248
View Trial

Whole-Pelvic Radiotherapy With a Stereotactic Body Radiotherapy Boost and Long-Term Androgen Deprivation for Unfavorable-Intermediate and High Risk Localized Adenocarcinoma of the Prostate.

  • Condition: Adenocarcinoma of the Prostate
  • Intervention: Radiation: Stereotactic Radiosurgical Boost3, Drug: Casodex, Drug: Leuprolide
  • Study ID: NCT02064036
View Trial

A Randomized Clinical Trial Comparing the Efficacy of MRI Versus PSA for Prostate Cancer Screening: The MVP Study (MRI vs PSA)

  • Condition: Prostate Cancer
  • Intervention: Device: Multi-parametric MRI, Other: PSA testing
  • Study ID: NCT02799303
View Trial

Pilot Study of Whole Gland Salvage HDR Prostate Brachytherapy for Locally Recurrent Prostate Cancer

  • Condition: Prostate Cancer Recurrent
  • Intervention: Radiation: HDR brachytherapy
  • Study ID: NCT02560181
View Trial

Primary Radical Prostatectomy Versus Primary Radiotherapy for Locally Advanced Prostate Cancer: an Open Randomized Clinical Trial

  • Condition: Prostatic Neoplasms
  • Intervention: Procedure: Prostatectomy/Surgery, Other: Radiotherapy with adjuvant androgen deprivation therapy
  • Study ID: NCT02102477
View Trial

Focal Low Dose Rate ( LDR) Brachytherapy: Hemi-ablative Treatment With LDR for Patients With Low and Low-tier Intermediate Risk Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Radiation: Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy
  • Study ID: NCT02643511
View Trial

Study of Stereotactic Body Radiotherapy (SBRT) for High-Risk Localized Prostrate Cancer

  • Condition: Adenocarcinoma of the Prostate, Stage III Prostate Cancer
  • Intervention: Radiation: stereotactic body radiation therapy, Other: quality-of-life assessment, Other: laboratory biomarker analysis, Drug: androgen deprivation therapy
  • Study ID: NCT02296229
View Trial

Phase II Study of Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate for Treatment of Localized, Non-Metastatic, High Risk Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Radiation: CyberKnife Boost
  • Study ID: NCT01508390
View Trial

Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer - a Prospective Single Center Phase I/II Study

  • Condition: Locally Advanced and Metastatic Prostate Cancer
  • Intervention: Procedure: Radical prostatectomy
  • Study ID: NCT02971358
View Trial

Molecular-Genetic Correlates of Fatigue in Cancer Patients Receiving Localized External Beam Radiation Therapy

  • Condition: Cancer, Fatigue
  • Study ID: NCT00852111
View Trial

Phase III Study of Image Guided Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate

  • Condition: Prostate Cancer
  • Intervention: Radiation: Radiation, Drug: Androgen Suppression Therapy
  • Study ID: NCT01492972
View Trial

The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older

  • Condition: Prostate Cancer
  • Intervention: Behavioral: Questionaires, Behavioral: Questionaires, Device: fMRI scan (optional)
  • Study ID: NCT00579072
View Trial

A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study

  • Condition: Prostate Cancer
  • Intervention: Drug: Metformin, Drug: Placebo
  • Study ID: NCT01864096
View Trial

Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy

  • Condition: Circulating Tumor Cells
  • Intervention: Other: Blood draw
  • Study ID: NCT02449837
View Trial

Phase I-II Study HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer With or Without Metastatic Disease

  • Condition: Prostatic Neoplasms
  • Intervention: Drug: HSV-tk +Valacyclovir in Combination with Brachytherapy
  • Study ID: NCT01913106
View Trial

68Ga-RM2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-contributory CT Scans

  • Condition: Prostate Adenocarcinoma
  • Intervention: Radiation: Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Procedure: Magnetic Resonance Imaging, Procedure: Positron Emission Tomography
  • Study ID: NCT02624518
View Trial

Phase II Clinical Study of Effect of Metformin on Prostate Specific Antigen Doubling Time

  • Condition: Prostate Cancer, Prostate Cancer Recurrent
  • Intervention: Drug: Metformin Hydrochloride Extended Release 750mg
  • Study ID: NCT02176161
View Trial

MRI-Guided HDR Brachytherapy for Prostate Cancer

  • Condition: Patients With Prostate Cancer
  • Intervention: Procedure: MRI Guided Needles to deliver HDR Brachytherapy, Procedure: MRI Guided Needles to deliver HDR Brachytherapy
  • Study ID: NCT00913939
View Trial

Safety and Efficacy of Salvage Lymph Node Dissection in Prostate Cancer Patients With Nodal Recurrence After Radical Prostatectomy With Curative Intent - a Prospective Single Center Phase I/II Study

  • Condition: Prostate Cancer Recurrent
  • Intervention: Procedure: Salvage lymph node dissection
  • Study ID: NCT02974075
View Trial

A Phase II Study With a Lead-in Safety Phase of Abiraterone in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)

  • Condition: Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Drug: Abiraterone Acetate, Drug: Niclosamide, Drug: Prednisone
  • Study ID: NCT02807805
View Trial

A Randomized-Controlled Trial of Transcutaneous Oestrogen Patches Versus LHRH Agonists in Prostate Cancer

  • Condition: Anemia, Cardiovascular Complications, Hot Flashes, Osteoporosis, Prostate Cancer
  • Intervention: Drug: Goserelin, Drug: Estradiol
  • Study ID: NCT00303784
View Trial

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

  • Condition: Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer
  • Intervention: Genetic: PCR/PCR/LDR Strategy
  • Study ID: NCT00579514
View Trial

Collection of Blood From Patients With Prostate Cancer

  • Condition: Prostatic Neoplasms
  • Study ID: NCT00923221
View Trial

Canary Prostate Active Surveillance Study

  • Condition: Prostatic Neoplasms
  • Study ID: NCT00756665
View Trial

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
  • Study ID: NCT00588185
View Trial

A Pilot Study of High Dose Rate Brachytherapy in The Radiation Oncology Branch

  • Condition: Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Prostate Cancer, Biliary Cancer
  • Intervention: Radiation: Brachytherapy
  • Study ID: NCT00924027
View Trial

A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.

  • Condition: Prostate Cancer
  • Intervention: Drug: Ra223, Drug: Enzalutamide
  • Study ID: NCT02194842
View Trial

Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene and Characterization of the Predisposition to Renal Cancer

  • Condition: Renal Tumor Histology, Cutaneous Leiomyomatosis, Kidney Cancer
  • Study ID: NCT00050752
View Trial

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

  • Condition: Malignant Neoplasms, Hereditary Neoplastic Syndromes, Kidney Cancer, Renal Cancer
  • Study ID: NCT00026884
View Trial

MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness

  • Condition: Prostatic Neoplasms, Genital Neoplasms, Male, Prostatic Diseases
  • Study ID: NCT01464216
View Trial

Multi-Institutional Registry for Prostate Cancer Radiosurgery. An IRB Approved Observational Trial

  • Condition: Prostate Cancer Early Risk Treated by Radiosurgery, Prostate Cancer Intermediate Risk Treated by Radiosurgery
  • Study ID: NCT01226004
View Trial

A Phase III Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial

  • Condition: Prostate Cancer, Prostate Adenocarcinoma
  • Intervention: Radiation: Standard Salvage Radiation Treatment (SSRT), Radiation: Mapped Tumor Salvage RT (MTSRT), Behavioral: Expanded Prostate Cancer Index Composite-SF12, Behavioral: Memory Anxiety Scale for Prostate Cancer patients, Behavioral: International Prostate Symptom Score (IPSS)
  • Study ID: NCT01411345
View Trial

A Phase II Randomized Control Trial of Conventional Versus Hypofractionated Radiation Regimen in Single Phase Using IMRT Technique and Long Term Androgen Suppression Therapy in High-risk Prostate Cancer Patients.

  • Condition: High-risk Prostate Cancer
  • Intervention: Radiation: Standard Radiation Treatment, Radiation: Hypofractionated radiation treatment
  • Study ID: NCT01488968
View Trial

Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy

  • Condition: Prostate Cancer
  • Intervention: Radiation: IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE, Radiation: Proton (prostate bed) to 70.2 CGE, Radiation: IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE, Radiation: Proton to 66.6 CGE
  • Study ID: NCT00969111
View Trial

A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy

  • Condition: Prostate Cancer
  • Intervention: Drug: 177Lu-J591, Drug: Ketoconazole, Drug: Hydrocortisone, Drug: 111In-J591
  • Study ID: NCT00859781
View Trial

A Phase III Prospective Randomized Trial of Standard-fractionation vs. Hypo-fractionation With Proton Radiation Therapy for Low Risk Adenocarcinoma of the Prostate

  • Condition: Prostate Cancer
  • Intervention: Radiation: Proton Radiation Hypofractionation, Radiation: Proton Radiation Standard Fractionation
  • Study ID: NCT01230866
View Trial

A Randomized Trial of Modifications to Radical Prostatectomy

  • Condition: Prostate Cancer
  • Intervention: Procedure: Lymph node template, Procedure: Transverse versus vertical closure, Drug: antibiotic prophylaxis
  • Study ID: NCT01407263
View Trial

Collection of Blood From Patients With Cancer for Analysis of Genetic Differences in Drug Disposition

  • Condition: Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma
  • Study ID: NCT01441089
View Trial

Biospecimen Acquisition From Human Subjects

  • Condition: Prostate Cancer, Breast Cancer, Colon Cancer, Lung Cancer, Liver Cancer
  • Study ID: NCT00034216
View Trial

Phase I/II Study of PROSTVAC in Combination With Nivolumab and / or Ipilimumab in Men With Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Biological: PROSTVAC-V/F, Drug: Nivolumab, Drug: Ipilimumab
  • Study ID: NCT02933255
View Trial

HDR Monotherapy for Prostate Cancer: A Feasibility Study of Focal Radiotherapy Yields

  • Condition: Prostate Cancer
  • Intervention: Radiation: targeted focal HDR brachytherapy, Radiation: Whole-gland HDR Brachytherapy
  • Study ID: NCT02918253
View Trial

A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers

  • Condition: Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma, Merkel Cell Carcinoma, Cutaneous T-Cell Lymphoma, Melanoma, Renal Cancer, Bladder Cancer, Prostate Cancer
  • Intervention: Drug: Durvalumab, Drug: Tremelimumab, Drug: Poly ICLC
  • Study ID: NCT02643303
View Trial